Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2010 - 2025)
Fennec Pharmaceuticals posted quarterly Total Non-Current Liabilities of $24.6 million for Q4 2025, down 44.05% year-on-year from $43.9 million in Q4 2024, and down 44.1% on a QoQ basis from $43.9 million in Q3 2025.
Fennec Pharmaceuticals (FENC) has 14 years of Total Non-Current Liabilities data on file, last reported at $24.6 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 44.05% year-over-year to $24.6 million; the trailing twelve-month figure through Dec 2025 stood at $24.6 million (down 44.05% YoY), and the FY2025 full-year result was $24.6 million, down 44.05% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $24.6 million, down from $43.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $56.8 million in Q2 2024 and bottomed at $4.0 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $25.4 million (2023), against an average of $29.0 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities soared 536.24%; it then plunged 44.05% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $5.0 million in 2021, then jumped by 399.18% to $24.9 million in 2022, then grew by 24.23% to $30.9 million in 2023, then jumped by 41.92% to $43.9 million in 2024, then slumped by 44.05% to $24.6 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $24.6 million (Q4 2025), $43.9 million (Q3 2025), and $43.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 24.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.56 Mn |
| Sep 30, 2025 | 43.94 Mn |
| Jun 30, 2025 | 43.93 Mn |
| Mar 31, 2025 | 43.91 Mn |
| Dec 31, 2024 | 43.90 Mn |
| Sep 30, 2024 | 56.66 Mn |
| Jun 30, 2024 | 56.77 Mn |
| Mar 31, 2024 | 56.34 Mn |
| Dec 31, 2023 | 30.93 Mn |
| Sep 30, 2023 | 25.65 Mn |
| Jun 30, 2023 | 25.39 Mn |
| Mar 31, 2023 | 25.14 Mn |
| Dec 31, 2022 | 24.90 Mn |
| Sep 30, 2022 | 24.69 Mn |
| Jun 30, 2022 | 3.99 Mn |
| Mar 31, 2022 | 4.49 Mn |
| Dec 31, 2021 | 4.99 Mn |
| Sep 30, 2021 | 4.99 Mn |
| Jun 30, 2021 | 4.99 Mn |
| Dec 31, 2018 | 1.64 Mn |
| Jun 30, 2018 | 680,000.00 |
| Mar 31, 2018 | 1.17 Mn |
| Dec 31, 2017 | 1.48 Mn |
| Jun 30, 2017 | 737,000.00 |
| Mar 31, 2017 | 356,000.00 |
| Dec 31, 2016 | 369,000.00 |
| Mar 31, 2016 | 306,000.00 |
| Dec 31, 2015 | 389,000.00 |
| Sep 30, 2015 | 338,000.00 |
| Jun 30, 2015 | 450,000.00 |
| Mar 31, 2015 | 429,000.00 |
| Dec 31, 2014 | 440,000.00 |
| Sep 30, 2014 | 402,000.00 |
| Jun 30, 2014 | 371,000.00 |
| Mar 31, 2014 | 211,000.00 |
| Dec 31, 2013 | 3.15 Mn |
| Dec 31, 2012 | 7.23 Mn |
| Dec 31, 2011 | 5.36 Mn |
| Dec 31, 2010 | 10.83 Mn |